AU6912996A - Liposomal phosphodiester, phosphorothioate, and p-ethoxy oligonucleotides - Google Patents

Liposomal phosphodiester, phosphorothioate, and p-ethoxy oligonucleotides

Info

Publication number
AU6912996A
AU6912996A AU69129/96A AU6912996A AU6912996A AU 6912996 A AU6912996 A AU 6912996A AU 69129/96 A AU69129/96 A AU 69129/96A AU 6912996 A AU6912996 A AU 6912996A AU 6912996 A AU6912996 A AU 6912996A
Authority
AU
Australia
Prior art keywords
oligonucleotides
phosphodiester
phosphorothioate
liposomal
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU69129/96A
Other languages
English (en)
Inventor
Gabriel Lopez-Berestein
Ana Maria Tari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of AU6912996A publication Critical patent/AU6912996A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Silicon Polymers (AREA)
AU69129/96A 1995-08-29 1996-08-26 Liposomal phosphodiester, phosphorothioate, and p-ethoxy oligonucleotides Abandoned AU6912996A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US520385 1995-08-29
US08/520,385 US5855911A (en) 1995-08-29 1995-08-29 Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
PCT/US1996/014146 WO1997007784A2 (en) 1995-08-29 1996-08-26 LIPOSOMAL PHOSPHODIESTER, PHOSPHOROTHIOATE, AND p-ETHOXY OLIGONUCLEOTIDES

Publications (1)

Publication Number Publication Date
AU6912996A true AU6912996A (en) 1997-03-19

Family

ID=24072378

Family Applications (1)

Application Number Title Priority Date Filing Date
AU69129/96A Abandoned AU6912996A (en) 1995-08-29 1996-08-26 Liposomal phosphodiester, phosphorothioate, and p-ethoxy oligonucleotides

Country Status (11)

Country Link
US (4) US5855911A (enExample)
EP (1) EP0847272B1 (enExample)
JP (1) JP4291412B2 (enExample)
AT (1) ATE253897T1 (enExample)
AU (1) AU6912996A (enExample)
CA (1) CA2228944C (enExample)
DE (1) DE69630691T2 (enExample)
DK (1) DK0847272T3 (enExample)
ES (1) ES2210385T3 (enExample)
PT (1) PT847272E (enExample)
WO (1) WO1997007784A2 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US6894031B1 (en) * 1996-11-21 2005-05-17 Cedars-Sinai Medical Center Pituitary tumor transforming gene (PTTG) carboxy-terminal peptides and methods of use thereof to inhibit neoplastic cellular proliferation and/or transformation
US6565889B2 (en) * 1996-12-02 2003-05-20 The Regents Of The University Of California Bilayer structure which encapsulates multiple containment units and uses thereof
US7262173B2 (en) 1997-03-21 2007-08-28 Georgetown University Chemosensitizing with liposomes containing oligonucleotides
US6126965A (en) * 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
AU733310C (en) 1997-05-14 2001-11-29 University Of British Columbia, The High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US6835395B1 (en) 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
AU7983798A (en) * 1997-06-23 1999-01-04 Sequus Pharmaceuticals, Inc. Liposome-entrapped polynucleotide composition and method
EP1012331B1 (en) * 1997-07-01 2006-03-29 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
DE19740092A1 (de) * 1997-09-12 1999-03-18 Ulrich Dr Med Hengge Liposomen und Verfahren zur Transfektion von Zellen
US7285288B1 (en) * 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) * 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
DE60037938T2 (de) 1999-02-26 2009-01-29 The University Of British Columbia, Vancouver Antisense-therapie für trpm-2
US7112337B2 (en) 1999-04-23 2006-09-26 Alza Corporation Liposome composition for delivery of nucleic acid
AU7868400A (en) 1999-10-08 2001-04-23 Alza Corporation Neutral-cationic lipid for nucleic acid and drug delivery
FR2802422B1 (fr) * 1999-12-21 2002-08-09 Capsulis Structures mixtes resultant de l'incorporation d'une macromolecule biologique, en particulier d'adn, dans une phase structuree d'amphiphiles et vesicules obtenues a partir de ces structures
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
US7196067B2 (en) 2000-09-14 2007-03-27 The University Of British Columbia Antisense insulin-like growth factor binding protein (IGFBP)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy
WO2003061386A1 (en) * 2002-01-03 2003-07-31 Board Of Regents, The University Of Texas System Wt1 antisense oligos for the inhibition of breast cancer
IL162540A0 (en) 2002-01-17 2005-11-20 Univ British Columbia Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
JP4620585B2 (ja) 2002-08-21 2011-01-26 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア クラステリンレベルを減少させることによる黒色腫の治療
CA2498026C (en) 2002-10-02 2015-06-30 The University Of British Columbia Compositions and methods for treatment of prostate and other cancers
MXPA05010499A (es) 2003-03-31 2006-05-25 Johnson & Johnson Particulas lipidicas que tienen un revestimiento lipidico asimetrico y metodo de preparacion de las mismas.
US8047981B2 (en) 2003-08-14 2011-11-01 Boston Scientific Scimed, Inc. Medical slings
WO2005030260A1 (en) * 2003-10-01 2005-04-07 The University Of British Columbia Bispecific oligonucleotide for the treatment of cns malignancies
CA2542886A1 (en) 2003-11-05 2005-05-19 Neelima M. Bhat Enhanced b cell cytotoxicity of cdim binding antibody
EP1691780A2 (en) 2003-11-21 2006-08-23 Alza Corporation Gene delivery mediated by liposome-dna complex with cleavable peg surface modification
WO2005094899A1 (en) 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
AU2005254105B2 (en) 2004-06-14 2012-01-12 Boston Scientific Limited Systems, methods and devices relating to implantable supportive slings
CN101098889A (zh) 2004-11-05 2008-01-02 盘林京有限公司 抗体导致的细胞膜损伤
EP1814595B1 (en) * 2004-11-23 2014-01-08 The University Of British Columbia Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels
ES2449196T3 (es) * 2005-04-06 2014-03-18 Boston Scientific Limited Conjunto para soporte suburetral
US8895717B2 (en) 2005-04-15 2014-11-25 The Board Of Regents Of The University Of Texas System Delivery of siRNA by neutral lipid compositions
EP1909687A1 (en) 2005-07-13 2008-04-16 Boston Scientific Scimed, Inc. Snap fit sling anchor system and related methods
US7981023B2 (en) * 2005-07-25 2011-07-19 Boston Scientific Scimed, Inc. Elastic sling system and related methods
WO2007014241A1 (en) 2005-07-25 2007-02-01 Boston Scientific Scimed, Inc. Pelvic floor repair system
US8273429B2 (en) * 2006-01-19 2012-09-25 Federal-Mogul World Wide, Inc. Fabric for end fray resistance and protective sleeves formed therewith and methods of construction
FR2900576B1 (fr) 2006-05-03 2008-09-19 Centre Nat Rech Scient Procede de concentration extemporanee et reversible de liposomes.
WO2008106781A1 (en) * 2007-03-05 2008-09-12 The University Of British Columbia Treatment of squamous cell carcinoma with hsp27 antisense oligonucleotides and radiotherapy
CN102112110A (zh) * 2008-06-06 2011-06-29 米尔纳医疗股份有限公司 用于RNAi试剂体内递送的新型组合物
ES2710109T3 (es) 2010-12-17 2019-04-23 Inst Nat Sante Rech Med Acidos nucleicos que se dirigen a TCTP para su uso en el tratamiento de cánceres quimiorresistentes u hormonorresistentes
US20120244209A1 (en) 2011-03-02 2012-09-27 Roth Jack A Tusc2 therapies
US9636201B2 (en) 2011-05-12 2017-05-02 Boston Scientific Scimed, Inc. Delivery members for delivering an implant into a body of a patient
US9113991B2 (en) 2011-05-12 2015-08-25 Boston Scientific Scimed, Inc. Anchors for bodily implants and methods for anchoring bodily implants into a patient's body
TWI606064B (zh) 2012-02-08 2017-11-21 Ｉｇｍ生物科技公司 細胞死亡誘導分子（ｃｄｉｍ）結合蛋白類及彼等之用途
CN103565745A (zh) 2012-08-10 2014-02-12 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
WO2014195754A1 (en) 2013-06-05 2014-12-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Hydrophobically modified antisense oligonucleotides comprising a triple alkyl chain
WO2014195755A1 (en) 2013-06-05 2014-12-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Hydrophobically modified antisense oligonucleotides comprising a ketal group
IL258625B2 (en) 2015-10-14 2025-02-01 Bio Path Holdings Inc P–ETHOXY NUCLEIC ACIDS FOR LIPOSOMAL FORMULATIONS
US10736880B2 (en) 2015-12-18 2020-08-11 The Board Of Regents Of The University Of Texas Systems Therapeutics for preterm labor management
US20190216735A1 (en) * 2016-09-14 2019-07-18 Nanyang Technological University Liposomal formulations
ES2928654T3 (es) 2016-09-16 2022-11-21 Bio Path Holdings Inc Terapia combinada con oligonucleótidos antisentido liposomales
WO2018071668A1 (en) 2016-10-12 2018-04-19 Board Of Regents, The University Of Texas System Methods and compositions for tusc2 immunotherapy
US20210115451A1 (en) * 2017-04-19 2021-04-22 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for igf-1r inhibition
EA201992490A1 (ru) 2017-04-19 2020-03-03 Байо-Пат Холдингз, Инк. Р-этокси нуклеиновые кислоты для ингибирования bcl2
CA3060090A1 (en) * 2017-04-19 2018-10-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for igf-1r inhibition
CA3058018A1 (en) 2017-04-19 2018-10-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for stat3 inhibition
CN115996707A (zh) 2020-04-20 2023-04-21 德克萨斯大学系统董事会 生物活性干粉组合物及其制造和使用方法
WO2022040435A1 (en) 2020-08-19 2022-02-24 The Board Of Regents Of The University Of Texas System Nanodrugs for targeted drug delivery and use thereof

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (enExample) * 1977-08-05 1981-02-13 Battelle Memorial Institute
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4469863A (en) * 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4480041A (en) * 1982-07-09 1984-10-30 Collaborative Research, Inc. Use of phosphotriester intermediates for preparation of functionalized liposomes
FR2540122B1 (fr) * 1983-01-27 1985-11-29 Centre Nat Rech Scient Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
US4721612A (en) * 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
US5202429A (en) * 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5094785A (en) * 1986-12-10 1992-03-10 Ciba Corning Diagnostics Corp. Process for stabilizing liposomes
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5030442A (en) * 1987-03-30 1991-07-09 Liposome Technology, Inc. Non-crystalline minoxidil composition
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5178875A (en) * 1991-01-14 1993-01-12 The Board Of Regents, The University Of Texas System Liposomal-polyene preliposomal powder and method for its preparation
US4950432A (en) * 1987-10-16 1990-08-21 Board Of Regents, The University Of Texas System Polyene microlide pre-liposomal powders
US4924624A (en) * 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5188897A (en) * 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
EP0397774A1 (en) * 1988-02-04 1990-11-22 Board Of Regents, The University Of Texas System Formulation and use of retinoids in treatment of cancer and other diseases
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5734033A (en) * 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
US5831066A (en) * 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5248671A (en) * 1989-02-15 1993-09-28 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5087617A (en) * 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
FR2644080A1 (fr) * 1989-03-13 1990-09-14 Trizac Jacques Dispositif de filtration et d'evacuation de petites particules, dechets et detritus, de natures diverses
ATE120640T1 (de) * 1989-04-18 1995-04-15 Vestar Inc Markierung mit liposomen von ischämischen geweben.
US5112962A (en) * 1989-04-19 1992-05-12 Northwestern University Labile anchors for solid phase polynucleotide synthesis
US5227170A (en) * 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
US5469854A (en) * 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
CA2033725C (en) * 1990-01-24 2001-05-29 Folker Pittrof Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991016901A1 (en) * 1990-04-30 1991-11-14 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of arachidonic acid metabolism
US5665710A (en) * 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
ES2099718T3 (es) * 1990-07-02 1997-06-01 Hoechst Ag Analogos de oligonucleotidos con uniones internucleotidicas de 3'-3' o 5'-5' terminales.
US5135917A (en) * 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US5378825A (en) * 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
JPH06501160A (ja) * 1990-09-17 1994-02-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 細胞の増殖をコントロールするための方法及び組成物
US5271941A (en) * 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
DE4110085A1 (de) * 1991-03-27 1992-10-01 Boehringer Ingelheim Int 2'-o-alkyl-oligoribonukleotide, verfahren zu deren herstellung und deren verwendung als antisense-oligonukleotide
FR2677272B1 (fr) * 1991-06-05 1995-03-03 Biovecteurs As Vecteur particulaire a tropisme selectif, procede de preparation et composition pharmaceutique.
CA2103377A1 (en) * 1991-06-18 1992-12-19 Bruno Calabretta Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligonucleotides
US5525719A (en) * 1991-08-30 1996-06-11 Chemgenes Corporation N-protected-2'-O-methyl-and N-protected-3'-O-methyl-ribonucleosides and their phosphoramidite derivatives
EP0724447B1 (en) * 1991-10-24 2003-05-07 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake
EP0616644B1 (en) * 1991-12-04 2003-07-02 E.I. Du Pont De Nemours And Company Fatty acid desaturase genes from plants
US5279957A (en) * 1992-04-30 1994-01-18 Washington University cDNA encoding human phospholipase A2 polypeptide
WO1993025673A1 (en) * 1992-06-04 1993-12-23 The Regents Of The University Of California In vivo gene therapy with intron-free sequence of interest
US5320962A (en) * 1992-07-22 1994-06-14 Duke University DNA encoding the human A1 adenosine receptor
NL9201440A (nl) * 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
AU5092893A (en) * 1992-09-02 1994-03-29 Georgetown University Method of encapsulating anthracycline glycosides in liposomes
US6001992A (en) 1999-01-07 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of novel anti-apoptotic bcl-2-related proteins
ATE200427T1 (de) 1992-10-21 2001-04-15 Univ Temple Die kombination von antineoplastischen mitteln und antisense-oligonukleotiden bei der behandlung von krebs
US6015886A (en) * 1993-05-24 2000-01-18 Chemgenes Corporation Oligonucleotide phosphate esters
US5417978A (en) * 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
FR2710074B1 (fr) * 1993-09-15 1995-12-08 Rhone Poulenc Rorer Sa Gène GRB3-3, ses variants et leurs utilisations.
ATE164515T1 (de) * 1993-11-05 1998-04-15 Amgen Inc Herstellung von liposomen und verfahren zur substanzverkapselung
US5651981A (en) * 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
US5696248A (en) * 1994-06-15 1997-12-09 Hoechst Aktiengesellschaft 3'-modified oligonucleotide derivatives
US5908635A (en) * 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
IT1275862B1 (it) * 1995-03-03 1997-10-24 Consiglio Nazionale Ricerche Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento
EP0739898B1 (de) * 1995-03-13 2001-09-26 Aventis Pharma Deutschland GmbH Phosphonomonoesternnukleinsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
EP0841068B1 (en) * 1995-06-01 2006-07-12 Kishimoto, Tadamitsu Leukemic cell growth inhibitor containing antisense oligonucleotide derivative against wilms' tumor gene (wt1)
US6326487B1 (en) * 1995-06-05 2001-12-04 Aventis Pharma Deutschland Gmbh 3 modified oligonucleotide derivatives
US5756122A (en) * 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
DE69634084T2 (de) * 1995-06-07 2005-12-08 Inex Pharmaceuticals Corp. Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
US5705385A (en) * 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
EP0843555B1 (en) * 1995-08-01 2003-08-27 Isis Pharmaceuticals, Inc. Liposomal oligonucleotide compositions
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
DE19532553A1 (de) * 1995-09-04 1997-03-06 Hoechst Ag Verfahren zur Herstellung substituierter N-Ethyl-Glycinderivate
US6120794A (en) * 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
US6977244B2 (en) * 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US5874224A (en) * 1997-03-11 1999-02-23 Incyte Pharmaceuticals, Inc. Growth factor receptor binding protein
US6126965A (en) * 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
GB9711919D0 (en) * 1997-06-09 1997-08-06 Ciba Geigy Ag Oligonucleotide derivatives
AU7983798A (en) * 1997-06-23 1999-01-04 Sequus Pharmaceuticals, Inc. Liposome-entrapped polynucleotide composition and method
US6277981B1 (en) * 1997-07-03 2001-08-21 Thomas Jefferson University Method for design and selection of efficacious antisense oligonucleotides
US7285288B1 (en) * 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US6136965A (en) * 1998-07-02 2000-10-24 The Regents Of The University Of California Deoxynucleic alkyl and alkoxy thiourea compounds
US6211162B1 (en) * 1998-12-30 2001-04-03 Oligos Etc. Inc. Pulmonary delivery of protonated/acidified nucleic acids
US6211349B1 (en) * 1998-12-30 2001-04-03 Oligos Etc., Inc. Protonated/acidified nucleic acids and methods of use
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers

Also Published As

Publication number Publication date
EP0847272A2 (en) 1998-06-17
DE69630691T2 (de) 2004-11-25
US20040005353A1 (en) 2004-01-08
US5855911A (en) 1999-01-05
ES2210385T3 (es) 2004-07-01
US20070202157A1 (en) 2007-08-30
PT847272E (pt) 2004-04-30
CA2228944C (en) 2011-10-18
CA2228944A1 (en) 1997-03-06
US7176302B2 (en) 2007-02-13
DE69630691D1 (de) 2003-12-18
WO1997007784A2 (en) 1997-03-06
ATE253897T1 (de) 2003-11-15
US7754872B2 (en) 2010-07-13
JP4291412B2 (ja) 2009-07-08
EP0847272B1 (en) 2003-11-12
JPH11512099A (ja) 1999-10-19
WO1997007784A3 (en) 1997-04-24
US6042846A (en) 2000-03-28
DK0847272T3 (da) 2004-03-22

Similar Documents

Publication Publication Date Title
AU6912996A (en) Liposomal phosphodiester, phosphorothioate, and p-ethoxy oligonucleotides
AU2946295A (en) Targeted gene delivery system
AU9023798A (en) Mdm2-specific antisense oligonucleotides
AU6617898A (en) An antisense oligonucleotide preparation method
AU3222795A (en) Antitumor antisense oligonucleotides
AU3739697A (en) Gene delivery system
ZA9811948B (en) Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom.
AU9663398A (en) Prize redemption system for games
IL118419A0 (en) Delivery vehicles comprising stable lipid/nucleic acid complexes
WO1998011211A3 (en) Method for using oligonucleotides having modified cpg dinucleosides
GB9510718D0 (en) Antisense oligonucleotides
AU5317496A (en) Single-stranded circular oligonucleotides
AU5883498A (en) Computerised gaming system
AU1266297A (en) Progressive gaming system
AU3775593A (en) Process for preparing phosphorothioate oligonucleotides
AU6185096A (en) Bingo game management method
AU8016494A (en) Antisense oligonucleotide generators
AU5441896A (en) Cooperative oligonucleotides
AU3999699A (en) Targeted liposomal drug delivery system
AU5259498A (en) Antisense oligonucleotides
GB9505438D0 (en) Antisense oligonucleotides
AU7803500A (en) Process for the preparation of phosphorothioate triesters and oligonucleotides
AU5683496A (en) Distributed gaming system
AU6186398A (en) Process for selecting anti-sense oligonucleotides
AU5319396A (en) Thiono triester modified antisense oligodeoxynucleotide phosphorothioates